BR112015017432A2 - métodos para o tratamento de indicações cardiovasculares - Google Patents

métodos para o tratamento de indicações cardiovasculares

Info

Publication number
BR112015017432A2
BR112015017432A2 BR112015017432A BR112015017432A BR112015017432A2 BR 112015017432 A2 BR112015017432 A2 BR 112015017432A2 BR 112015017432 A BR112015017432 A BR 112015017432A BR 112015017432 A BR112015017432 A BR 112015017432A BR 112015017432 A2 BR112015017432 A2 BR 112015017432A2
Authority
BR
Brazil
Prior art keywords
methods
treating cardiovascular
cardiovascular indications
treating
indications
Prior art date
Application number
BR112015017432A
Other languages
English (en)
Portuguese (pt)
Inventor
Holzmeister Johannes
Original Assignee
Cardiorentis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ltd filed Critical Cardiorentis Ltd
Publication of BR112015017432A2 publication Critical patent/BR112015017432A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
BR112015017432A 2013-01-25 2014-01-24 métodos para o tratamento de indicações cardiovasculares BR112015017432A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756692P 2013-01-25 2013-01-25
PCT/IB2014/000253 WO2014115033A2 (en) 2013-01-25 2014-01-24 Methods of treating cardiovascular indications

Publications (1)

Publication Number Publication Date
BR112015017432A2 true BR112015017432A2 (pt) 2017-07-11

Family

ID=50382492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017432A BR112015017432A2 (pt) 2013-01-25 2014-01-24 métodos para o tratamento de indicações cardiovasculares

Country Status (19)

Country Link
US (2) US20140213520A1 (cg-RX-API-DMAC7.html)
EP (1) EP2948165A2 (cg-RX-API-DMAC7.html)
JP (1) JP2016505065A (cg-RX-API-DMAC7.html)
KR (1) KR20150108903A (cg-RX-API-DMAC7.html)
CN (1) CN105025918A (cg-RX-API-DMAC7.html)
AP (1) AP2015008624A0 (cg-RX-API-DMAC7.html)
AU (1) AU2014208851B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015017432A2 (cg-RX-API-DMAC7.html)
CA (1) CA2898571A1 (cg-RX-API-DMAC7.html)
DO (1) DOP2015000175A (cg-RX-API-DMAC7.html)
EA (1) EA201500765A1 (cg-RX-API-DMAC7.html)
IL (1) IL239909A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015009606A (cg-RX-API-DMAC7.html)
NZ (1) NZ710246A (cg-RX-API-DMAC7.html)
PH (1) PH12015501559A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201505492XA (cg-RX-API-DMAC7.html)
TN (1) TN2015000315A1 (cg-RX-API-DMAC7.html)
TW (1) TW201442722A (cg-RX-API-DMAC7.html)
WO (1) WO2014115033A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184248A1 (en) * 2014-05-30 2015-12-03 Concert Pharmaceuticals, Inc. Methods of treating fibrotic diseases
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN110278941B (zh) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
WO1995033769A1 (de) 1994-06-02 1995-12-14 Boehringer Mannheim Gmbh Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP2004510743A (ja) * 2000-10-04 2004-04-08 モレキュラー メディシン リサーチ インスティチュート レラキシンのアゴニストまたはアンタゴニストの投与によるアポトーシスを調節する方法
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7732406B2 (en) * 2005-04-07 2010-06-08 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
WO2009034134A2 (en) * 2007-09-11 2009-03-19 Pharis Biotec Gmbh Use of natriuretic peptides for treating angioedema syndromes
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
AU2009246112B2 (en) * 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure
US8642550B2 (en) * 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
JP2010116325A (ja) * 2008-11-11 2010-05-27 Institute For Protein Science Co Ltd Sirs患者を救命するためのペプチド組成物
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
PH12012500562A1 (en) * 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
EP2547356A1 (en) * 2010-03-15 2013-01-23 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
EP2605797A2 (en) * 2010-08-20 2013-06-26 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
EA201500765A1 (ru) 2015-12-30
WO2014115033A3 (en) 2015-02-26
AP2015008624A0 (en) 2015-07-31
DOP2015000175A (es) 2015-11-15
CN105025918A (zh) 2015-11-04
MX2015009606A (es) 2016-04-26
TN2015000315A1 (en) 2017-01-03
US20140213519A1 (en) 2014-07-31
SG11201505492XA (en) 2015-08-28
CA2898571A1 (en) 2014-07-31
PH12015501559A1 (en) 2015-09-21
US20140213520A1 (en) 2014-07-31
JP2016505065A (ja) 2016-02-18
NZ710246A (en) 2016-11-25
KR20150108903A (ko) 2015-09-30
AU2014208851B2 (en) 2016-12-22
WO2014115033A2 (en) 2014-07-31
AU2014208851A1 (en) 2015-08-06
TW201442722A (zh) 2014-11-16
IL239909A0 (en) 2015-08-31
EP2948165A2 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
BR112015022197A2 (pt) tratamento de cataplexia
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112014013780A8 (pt) transportador de seringa
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
BR112015006731A2 (pt) combinações e usos das mesmas
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112015021681A2 (pt) proteínas de ligação para pcsk9
BR112014011223A2 (pt) método de tratar uma doença proliferativa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]